News & Events

• March 17, 2023
  

  The Rare Disease Clinical Outcome Assessment Consortium: Aiming to Fulfill Unmet Drug Development Endpoint Measurement Needs

  Appropriate endpoint selection for rare disease trials is challenging. The Rare Disease Clinical Outcome Assessment (COA) Consortium’s aim is the creation of a resource of publicly available COAs deemed fit-for-purpose as trial endpoint measures. You can view the full presentation here....
• June 9, 2022
  

  C-Path Launches Unique Translational Therapeutics Accelerator with Support from Cottrell Foundation

  C-Path today announced it has been awarded a grant from the Frederick Gardner Cottrell Foundation, a non-profit organization established by Research Corporation Technologies, Inc. (RCT) that provides financial support for scientific research and educational programs, to create the C-Path Translational Therapeutics Accelerator (TRxA). The accelerator is a unique, global effort focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients.

• May 14, 2020
  

  Serum Glutamate Dehydrogenase Activity Enables Early Detection of Liver Injury in Subjects with Underlying Muscle Impairments

  King, Amy C. Porter, Jane Owens, et al. “Serum Glutamate Dehydrogenase Activity Enables Early Detection of Liver Injury in Subjects with Underlying Muscle Impairments.” PloS One 15, no. 5 (2020): e0229753. https://doi.org/10.1371/journal.pone.0229753.

• April 10, 2020
  

  ePRO Consortium Announces COVID-19 Risk Assessment and Mitigation Strategies for Sponsors and eCOA Providers for Collection of PRO Data through Clinical Sites

  In collaboration with C-Path’s PRO Consortium, the ePRO Consortium has developed the presentation titled “Coronavirus Disease 2019 (COVID-19): Risk Assessment and Mitigation Strategies for the Collection of Patient-Reported Outcome (PRO) Data through Clinical Sites.” This presentation focuses on the current challenges of capturing PRO data originally intended to be collected electronically (i.e., ePRO) from study participants during in-person visits to study sites. Recommended risk assessment and mitigation strategies for consideration by trial sponsors and eCOA providers to facilitate the continued collection of PRO data in clinical trials are provided.

  Access the PDF: COVID-19: Risk Assessment and Mitigation Strategies for the Collection of Patient-Reported Outcome Data through Clinical Sites

• September 9, 2019 - September 10, 2019
  

  Solutions to Drug Development Challenges Workshop: Utilizing Quantitative Approaches, Data Sharing, and Novel Biomarkers

    Title Presenter Presentation Link Introduction Dr. John-Michael Sauer (C-Path) Keynote Address Dr. Joseph Scheeren (C-Path)   Welcoming Remarks Dr. Janet Woodcock (US FDA) Session 2: Benefits of DDT progression to regulatory acceptance Moderators: Dr. Inish O’Doherty (C-Path) and Dr. Ameeta Parekh (US FDA) 2.1 A perspective on the history and evolution of drug development......